色噜噜av一区二区三区,午夜精品久久久久久久爽

您好，歡迎來到拜力生物網(wǎng)站！請(qǐng)登錄注冊(cè)

我的訂單 | 聯(lián)系我們 | 在線客服QQ：3012681483 | 客服電話：400-968-7988 | 工作時(shí)間：08:30-17:30

主營產(chǎn)品： ELISA試劑盒、抗體、補(bǔ)體血清、兔補(bǔ)體、干擾素、小鼠測溫儀、進(jìn)口試劑、Quidel代理、Swant代理、PBL Assay Science代理

網(wǎng)站首頁產(chǎn)品中心代理品牌新聞資訊資源中心關(guān)于我們

所在位置：首頁 > 產(chǎn)品中心 > Xcessbio > Xcessbio產(chǎn)品

訂購信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

RO4929097,γ-SecretaseInhibitor

品牌：Xcessbio

貨號(hào)：M60007-2s

規(guī)格：2 mg solid

貨期：

應(yīng)用：

咨詢客服

立即購買加入購物車

RO4929097,γ-SecretaseInhibitor

商品詳情參考文獻(xiàn) 相關(guān)資料

Product Information

Molecular Weight:	469.40
Formula:	C₂₂H₂₀F₅N₃O₃
Purity:	≥98%
CAS#:	847925-91-1
Solubility:	DMSO up to 100 mM
Chemical Name:	N1-[(7S)-6,7-Dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)propanediamide
Storage:	Powder: 4^oC 1 year. DMSO: 4^oC 3 month; -20^oC 1 year.

Biological Activity:?
RO4929097 is a highly potent and selective γ-secretase inhibitor with an IC₅₀ ~4 nM. It can cause a dramatic reduction of the intracellular Notch level and lead to significantly decreased expression of the Notch transcriptional target genes, such as Hes1. It exhibits potent inhibitory activity of Notch signaling in tumor cells. Currently RO4929097 is in multiple phase I/II clinical trials to treat cancer.

How to Use:

In vitro: RO4929097 was used at 1-10 μM in vitro.
In vivo: RO4929097 was administered orally at 10 mg/kg with an intermittent or daily schedule and showed anti-tumor activity in multiple tumor xenograft models.

Reference:

1. Luistro L, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. (2009) Cancer Res. 69(19):7672-80.
2. He W, et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. (2011) Mol Oncol. 5(3):292-301.
3. Huynh C, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. (2011) PLoS One. 6(9):e25264.